Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Therapy: Preclinical

Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation

Meir Wetzler, Michael T. Brady, Erin Tracy, Zhang-Rong Li, Kathleen A. Donohue, Kieran L. O'Loughlin, Yijun Cheng, Amir Mortazavi, Amy A. McDonald, Padmaja Kunapuli, Paul K. Wallace, Maria R. Baer, John K. Cowell and Heinz Baumann
Meir Wetzler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael T. Brady
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Tracy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhang-Rong Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen A. Donohue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kieran L. O'Loughlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yijun Cheng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Mortazavi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy A. McDonald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Padmaja Kunapuli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul K. Wallace
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria R. Baer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John K. Cowell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heinz Baumann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-06-1354 Published November 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Arsenic trioxide decreases proliferation of acute myeloid leukemia (AML) cells, but its precise mechanism of action is unknown.

Experimental Design: We studied the effect of arsenic trioxide on patient samples and the AML cell line HEL, which, like leukemic blasts from 50% of AML cases, has constitutively activated signal transducer and activator of transcription (STAT) proteins.

Results: Arsenic trioxide induced mitotic arrest starting at 24 hours and significant cell death at 48 hours. These events were preceded by an arsenic trioxide dose-dependent down-regulation of activated STAT proteins starting at 6 hours. We hypothesized that arsenic trioxide inhibits protein tyrosine kinases (PTK), which, among others, phosphorylate and activate STATs. We therefore studied arsenic trioxide effects on Janus kinases and on three oncogenic PTKs that are known to activate STATs [FLT3, ZNF198/fibroblast growth factor receptor 1 (FGFR1), and BCR/ABL]. Arsenic trioxide reduced STAT3 activation by Janus kinases, altered phosphorylation and electrophoretic mobility of ZNF198/fibroblast growth factor receptor 1, reduced kinase protein level, and decreased STAT3 protein phosphorylation. Arsenic trioxide also reduced the phosphorylation of BCR/ABL and FLT3 with corresponding decreased STAT5 phosphorylation.

Conclusions: These results suggest a selective activity of arsenic trioxide on PTKs and will assist in developing clinical trials in AML.

  • Leukemias and lymphomas
  • Signal transduction
  • CELLULAR, MOLECULAR, AND TUMOR BIOLOGY
  • Signal transduction pathways
  • Oncogenic transcription factors: leukemias/lymphomas/solid tumors

Acute myeloid leukemia (AML) is frequently associated with chromosomal abnormalities, but these are generally neither necessary nor sufficient for leukemogenesis; additional transforming events or growth stimulatory processes are needed. Because leukemic blasts require growth factor(s) for their survival even in the seemingly most aggressive cases, the signal transduction pathways engaged by these growth factors likely provide the necessary growth-supporting function. The signal transducer and activator of transcription (STAT) proteins are a class of mediators that are often dysregulated in AML (1). One of the mechanisms of dysregulation of STAT proteins in AML is constitutive activation (2). Constitutive STAT3 activation, observed in samples from ∼50% of AML patients, may result from the expression of oncogenic protein tyrosine kinases (PTK) or from autocrine stimulation by hematopoietic growth factors. We have shown that disease-free survival is significantly shorter in AML patients whose leukemia cells exhibit constitutive STAT3 activity, compared with those with cells without constitutive activity (3).

Arsenic trioxide (As2O3; Trisenox) has recently emerged as a promising therapeutic agent in leukemia. Arsenic trioxide proved to be effective in inducing remission in patients with acute promyelocytic leukemia (4). Therapeutic success in acute promyelocytic leukemia prompted in vitro testing of arsenic trioxide in other types of leukemia (5, 6), and arsenic trioxide was found to induce apoptosis and necrosis of AML cells. The precise mechanism(s) of action of arsenic trioxide are unclear, although several cellular effects have been identified, including up-regulation of the various forms of mitogen-activated protein kinases, inhibition of Janus-activated kinases (JAK) and IκB kinase, and down-regulation of STAT and nuclear factor-κB proteins (7, 8). Because leukemia cells depend on growth factors for their survival, we tested the effect of arsenic trioxide on cell proliferation, apoptosis, and cytokine signal transduction pathways that are known to promote survival or growth of AML cells. We found that the decrease in cell proliferation induced by arsenic trioxide is preceded by modulation of the signal transduction pathways in AML blasts through attenuation of all PTKs studied. Understanding the biological effects of arsenic trioxide are of particular importance as it emerges as a novel treatment approach in AML. Moreover, the effects, even when not directly involved in suppression of proliferation, are surrogate markers for arsenic trioxide action.

Materials and Methods

Materials

All chemicals were purchased from Sigma Chemicals (St. Louis, MO) unless otherwise specified. Granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and arsenic trioxide were kindly provided by Amgen (Thousand Oaks, CA), Immunex (Seattle, WA), and Cell Therapeutic, Inc. (Seattle, WA), respectively.

Patient samples

Bone marrow samples were collected from four AML patients with >80% blasts at diagnosis. Two of the patients had complex karyotypes [02472 (French-American-British M6) and 02448 (French-American-British M2)], one had inv(16) [02537 (French-American-British M5a)], and one had normal karyotype with internal tandem duplication (ITD) of FLT3 [04153 (French-American-British M2)]. Light-density bone marrow cells were isolated by 1.077 g/mm3 Ficoll-Hypaque density gradient centrifugation and were cryopreserved using standard techniques. Cells were thawed before study. The study was approved by the Roswell Park Cancer Institute Scientific Review Committee and Institutional Review Board. All patients signed informed consent.

Cell lines

Cell lines used in the study included the AML cell line (HEL), a cytokine-independent human erythroleukemia cell line that carries the JAK2 V617F mutation (9) and has constitutive STAT activity, and the AML cell line constitutively expressing wild-type FLT3 (EOL-1). The human hepatoma cell line (HepG2) served as an example of a nonhematopoietic tumor line with gene induction and suppression of proliferation dependent on a cytokine-regulated STAT3 pathway (10). The human epithelial kidney 293 cell line was used for PTK expression by transfection (11).

Culture conditions

HEL and EOL-1 cells were exposed to arsenic trioxide at concentrations ranging from 0.25 to 4 μmol/L for 6 to 48 hours. HepG2 and 293 cells were exposed to arsenic trioxide at concentrations of 0.2 to 5 μmol/L for 6 to 24 hours to maximize the arsenic trioxide effect. HEL cells were also exposed to freshly prepared 100 μmol/L to 1 mmol/L sodium orthovanadate to inhibit protein-tyrosine phosphatase activities (12).

Cell proliferation and viability

Viability was determined by the trypan blue dye (Life Technologies, Gaithersburg, MD) exclusion assay. Apoptosis was analyzed with the Annexin-V-Fluos staining kit (Roche, Indianapolis, IN), following the manufacturer's directions; cells were evaluated on the FACSCalibur. Data analysis was done with WinList.

Morphologic analysis

To study the morphology of cells exposed to arsenic trioxide, cytospins were prepared at each time point. Following fixation with methanol, cells were stained with Giemsa May-Grünwald stain and analyzed by light microscopy (Nikon, Inc., Melville, NY).

Cell cycle analysis

DNA content was determined after ethanol fixation by staining the cells with propidium iodine in the presence of RNase. Cytofluorometric analysis was done using a FACScan (Becton Dickinson, San Jose, CA) flow cytometer equipped with a 488-nm argon line. Propidium iodine fluorescence was evaluated using linear amplification in the FL2 channel (585/42 band-pass filter). Data analysis was done with WinList and ModFit LT software for Windows (both from Verity Software House, Inc., Topsham, ME).

Transfection

To study the effect of arsenic trioxide of individual PTKs, 293 cells were transfected with expression vectors for the PTKs ZNF198/fibroblast growth factor receptor (FGFR1; ref. 11), green fluorescent protein–tagged ZNF198/FGFR1 (11), BCR/FGFR1 (13), p210BCR/ABL (14), promyelocytic leukemia (PML; ref. 15), JAK1 (16), and JAK2 (17) using the calcium phosphate methods (18). After 24 hours of culturing, the transfected cells were subdivided for treatment. The gene regulatory effects of arsenic trioxide were studied in HepG2 cells transiently transfected with the STAT3-responsive reporter gene construct p(5xHPX-IL-6RE)-CAT (19) and the expression vectors for PTKs, as previously described (18). Subcultures of transfected HepG2 cells were treated with arsenic trioxide or interleukin-6 (IL-6), and the relative change in the expression of the CAT reporter gene was quantitated 24 hours later (18).

Western blotting

Tyrosine phosphorylated and nonphosphorylated STAT1, STAT3, STAT5A, STAT5B, JAK1, JAK2, extracellular signal-regulated kinase (ERK) 1/2, c-Jun NH2-terminal kinase (JNK), ZNF198/FGFR1, BCR/FGFR1, BCR/ABL, and PML proteins were quantitated by Western blot analysis as previously described (2, 3). In brief, whole-cell extracts were separated on 6% or 7.5% polyacrylamide SDS gels, and the proteins were transferred onto nitrocellulose membranes. The membranes were incubated with antibodies against phosphorylated STAT1 (Y701), STAT3 (Y705), STAT5A/B (Y694/Y699), ERK1/2, JNK (Upstate Biotechnology, Lake Placid, NY), ABL (Cell Signaling Technology, Inc., Beverly, MA), and phosphotyrosine (PY20 and M1; Transduction Laboratories, Lexington, KY). To detect nonphosphorylated proteins, immunoblots were reacted with antibodies against the NH2 termini of STAT1, STAT3, STAT5, ERK1/2, JNK (Transduction Laboratories), JAK1, JAK2, FGFR1, PML (sc-5621), and BCR (N-20; Santa Cruz Biotechnology, Santa Cruz, CA). The protein inhibitor of activated STAT3 (PIAS3) was detected with anti-PIAS3 (Abgent, San Diego, CA). To detect phosphorylated FLT3 expression, cell lysates were incubated at 4°C overnight with anti-FLT3 antibody (S18; Santa Cruz Biotechnology), then protein A agarose (Upstate Biotechnology) was added for an additional 2 hours (20). After electrophoresis and transfer to nitrocellulose membranes, immunoblotting was done using anti phosphotyrosine antibody 4G10 (Upstate Biotechnology) to assess phosphorylated FLT3 or with anti-FLT3 antibody to measure total FLT3. When necessary, anti-actin antibody (Santa Cruz Biotechnology) was used to show equal loading. The immune complexes were visualized by the enhanced chemiluminescence reaction (Amersham Life Science, Arlington Heights, IL).

Electrophoretic mobility shift assay

The DNA-binding activity of STAT3 and STAT5 in the absence of cytokine or growth factor treatment was assessed by electrophoretic mobility shift assay. Whole-cell extracts prepared from HEL cells as previously described (2, 3) were incubated with 32P-labeled oligomers corresponding to the high-affinity binding element for STAT3, SIE (21), and STAT5 (TB2; ref. 22). The complexes were analyzed by 5% PAGE and autoradiography. Relative DNA-binding activity was determined by densitometry of the autoradiographs; the activity detected in extract from HEL cells served as standard and was defined as 100%. The detection limit of the electrophoretic mobility shift assay system was set at <2%. The identity of the STAT-containing complexes was determined by antibody supershift with the COOH-terminal–specific anti-STAT3 (C-20) or anti-STAT5 (C-17) monoclonal antibody (Santa Cruz Biotechnology).

In vitro arsenic trioxide reaction with ZNF198/FGFR1

ZNF198/FGFR1–transfected 293 cells were subdivided into two cultures. After an additional 1-day culture period, one culture was treated for 30 minutes at 37°C with medium alone and the other culture with medium containing 5 μmol/L arsenic trioxide. The cells were washed with ice-cold PBS and homogenized in the same buffer (1 × 107/mL) using a tight-fitted Dounce homogenizer. Cell debris was removed by centrifugation for 10 minutes at 13,000 × g followed by preparation of the cytosolic fraction by centrifugation for 1 hour at 105,000 × g. PBS alone or PBS containing 5 μmol/L and 10-fold serially diluted arsenic trioxide were added to 4 μL of cytosol aliquots. These mixtures were incubated for 30 minutes at 37°C. The reactions were stopped by adding 15 μL of SDS sample buffer and boiling for 5 minutes. The apparent molecular size of ZNF198/FGFR1 was determined by SDS-PAGE and immunoblotting.

Statistical methods

The following variables of arsenic trioxide effect on HEL cells were evaluated: total number of cells, percentage of necrotic and apoptotic cells, and activity levels of phosphorylated STAT1, STAT3, STAT5 and ERK1/2, and expression levels of total STAT3 protein. The mean and variance were calculated for each set of replicates within each experimental condition. The effects of dose and time were evaluated using the Hill model (23, 24). Model goodness-of-fit was checked by plotting the actual versus predicted values, and by evaluating the 95% confidence intervals (95% CI) for variable estimates.

Due to the limited range of dose levels, only exploratory analyses were employed using nonparametric methods to compare phosphorylated and total STAT3 expression levels among the dose levels. To control the overall type I error rate at 10%, a Bonferonni adjustment (25) was made so that the level of significance for each statistical test was set at 0.008.

Pharmacodynamic models. The inhibitory effects of arsenic trioxide on cell proliferation and the phosphorylation of STAT1, STAT3, and STAT5 were analyzed using the Hill model equation (Eq. A) below (24). In this equation, C is the drug concentration, E is the measured effect, Econ is the control level observed when no drug is present, B is the background level observed at high drug concentration, and IC50 is the drug concentration inducing 50% inhibition of the maximal effect (Econ − B). The slope variable γ corresponds to a shallow concentration-effect curve when its absolute value is <1 and corresponds to a steeper curve as its absolute value becomes >1. A negative sign of γ indicates an inhibitory effect.Math

Due to the limited number of replicates, the background variable B was fixed at its mean value, so that the other variables could be estimated with more precision.

A modification was made in the model for phosphorylated STAT1 activity, in which a fixed background level was not assumed due to wide variation in the data at 1 μmol/L arsenic trioxide. Instead, background was estimated as a separate variable in this model.

The effect of arsenic trioxide concentration on apoptosis was of a stimulatory nature, whereby increased drug concentrations were associated with increased percentages of apoptotic cells. The structural equation providing the best fit for these data was a modified version of the Emax model. In this structural equation, the minimum level is the control level when no drug is present (Econ), and the maximal effect is equal to the effect seen at the highest dose level (Emax). Setting Econ equal to its mean value in the equation yielded a more parsimonious model (Eq. B).Math

Equation B was also used to model the effect of arsenic trioxide dose on the percentage of dead (both necrotic and apoptotic) cells.

Results

Arsenic trioxide decreases phosphorylated STAT3 activity in patient samples. We first tested the effect of arsenic trioxide on STAT phophorylation in primary AML blasts with constitutively activated STAT3. Cells from three AML patients were treated with two doses of arsenic trioxide for 6 hours and the level of phosphorylated STAT3 was determined (Fig. 1A ). In each case, a reduction of tyrosine phosphorylated STAT3 was evident. Of note is that arsenic trioxide had no appreciable effect on the total STAT3 protein level, suggesting that arsenic trioxide specifically decreases the relative amount of activated STAT3. To ensure that the effect was STAT3-specific, we studied the effect of arsenic trioxide on phosphorylated and total ERK1/2 activity in the patient samples. As shown in Fig. 1A (bottom), arsenic trioxide did not reduce the basal level phosphorylation of ERK1/2 in the patient samples. In fact, the cells from one patient, 02448, which showed a low basal ERK phosphorylation compared with the cells from other two patients, responded to arsenic trioxide by an increased ERK phosphorylation that may be related to a particularly strong stress response. To evaluate the effect of arsenic trioxide on PTKs upstream of the STAT proteins, we studied a sample from an AML patient with normal karyotype but with FLT3-ITD. As shown in Fig. 1B (left), arsenic trioxide induced down regulation of FLT3-ITD and STAT5. Similar results were observed in the AML cell line, EOL-1, expressing consitutively active FLT3 (Fig. 1B, right).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Arsenic trioxide (ATO) down-regulates STAT activity in AML blasts. Cells were exposed to arsenic trioxide at two concentrations for 6 hours. A, samples from three AML patients with no known oncogenic PTK activity. Arsenic trioxide induced minimal phosphorylation of ERK1/2 in the sample from patient 02448 but not in the other two patient samples. B, left, a sample from a patient with FLT3-ITD showing down-regulation of FLT3-ITD and phosphorylated STAT5 by 4 μmol/L arsenic trioxide; right, control EOL-1 cells with constitutively active FLT3. WB, Western blot.

Arsenic trioxide inhibits cell proliferation. HEL cells, like 50% of AML cases, express constitutive STAT activities and therefore were used here as a tissue culture model (9). When treated with arsenic trioxide for 6 or 24 hours, no appreciable effect on cell number was detected. Following 48 hours, HEL cells showed decreased proliferation (Fig. 2A ). The arsenic trioxide IC50 concentration was calculated to be 1.23 μmol/L (95% CI, 0.94-1.53). To understand the mechanism leading to the reduced cell counts at 48 hours, percentages of necrotic and apoptotic cells were analyzed at 48 hours. The IC50 for necrotic cells was equal to 0.98 μmol/L (95% CI, 0.26-1.69), whereas the IC50 for apoptotic cells was 1.71 μmol/L (95% CI, −0.19 to 3.61). This indicated that arsenic trioxide caused necrosis at a lower concentration level during the 2-day treatment period in HEL cells.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Arsenic trioxide decreases survival of HEL cells through an arrest at the G2-M stage of the cell cycle. A, Hill model curve showing the effect of arsenic trioxide at different concentrations on total cell count at 48 hours. B, mitotic arrest (right) induced by arsenic trioxide at 24 hours compared with control (left) cells (May-Grünwald stain; magnification, ×40). C and D, cell cycle analysis of control cells showing 9% cells in G2-M (C), and cells treated with 4 μmol/L arsenic trioxide for 24 hours showing 20% cells in G2/M (D).

Arsenic trioxide induces mitotic arrest. HEL cells were exposed to 4 μmol/L arsenic trioxide for 6, 24, and 48 hours. Mitotic arrest with chromosome condensation and disappearance of the nuclear envelope was first detected at 24 hours (Fig. 2B). This was associated with a decrease in cells entering the cycle with an increase in G2-M phase cells detected by flow cytometry (Fig. 2C and D).

Arsenic trioxide modulates signal transduction pathways. HEL cells exposed to arsenic trioxide for 6 hours showed a sharp decrease in constitutive STAT1, STAT3, and STAT5 activities but not in the total level of these proteins, suggesting an arsenic trioxide–mediated reduction of activation and/or enhanced dephosphorylation (deactivation; Fig. 3 ). The results obtained for the DNA-binding activity of the STAT proteins by electrophoretic mobility shift assay and for relative level of tyrosine phosphorylation by Western blotting were highly complementary (Fig. 3A, top). The IC50 for phosphorylated STAT1 was 0.72 μmol/L (95% CI, 0.19-1.25), and the slope variable was −2.24 (95% CI, −5.30 to 0.83), indicating a relatively steep decline in phosphorylated STAT1 as the arsenic trioxide dose level increased (Fig. 3B). Similarly, the IC50 for phosphorylated STAT3 at 6 hours was 0.91 μmol/L (95% CI, 0.19-1.63), and the slope variable γ was −1.19 (95% CI, −1.96 to −0.43; Fig. 3C). Finally, the IC50 for phosphorylated STAT5 was 0.32 μmol/L (95% CI, 0.20-0.44), and the slope variable was estimated to be −2.50 (95% CI, −3.95 to −1.05; Fig. 3D). The effect of arsenic trioxide was most pronounced on phosphorylated STAT5. The relative level of tyrosine phosphorylated STAT proteins continued to decrease during treatments longer than 6 hours, along with the decrease in survival. Removal of arsenic trioxide after 6 hours resulted in recovery of the phosphorylated STAT3 and STAT5 levels to baseline at 24 hours (data not shown). Similarly, there was no effect on cell survival after arsenic trioxide removal.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Arsenic trioxide down-regulates constitutive STAT1, STAT3, and STAT5 activities in HEL cells. Cells were exposed to arsenic trioxide at different concentrations for 6 hours. A, Western blotting and electrophoretic mobility shift assay (EMSA) showing the SIE-binding activity of STAT1 and STAT3 (top) analyses and Western blotting showing STAT5 activity (bottom). B to D, Hill model analyses of cumulative Western blotting data for phosphorylated STAT1 (B), STAT3 (C), and STAT5 (D) from multiple experiments.

To test whether arsenic trioxide affected the mitogen-activated protein kinase pathway, arsenic trioxide activity on ERK1/2 phosphorylation level was determined. As shown in Fig. 4 (top), there was no appreciable specific effect of arsenic trioxide on ERK1/2 in HEL cells following 6 hours of incubation. The Hill model could not be derived. Because arsenic trioxide treatment could conceivably introduce a chemical stress response, the activation of the stress mitogen-activated protein kinase was also analyzed by immunoblotting for phosphorylated JNK. A prominent immune signal for phosphorylated JNK was observed that did not change as a function of arsenic trioxide treatment (Fig. 4, middle). A modification of STAT function through enhanced expression of PIAS3 by arsenic trioxide was ruled out by identifying a constant level of PIAS3 protein on immunoblots (Fig. 4, bottom). These data suggest, at least, relative specificity of arsenic trioxide for the STAT pathway.

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Arsenic trioxide does not affect phosphorylation of ERK1/2 or JNK and does not modify PIAS3 levels. Western blot analysis following 6 hours of incubation with arsenic trioxide.

It is conceivable that arsenic trioxide achieved reduced phosphorylation of STATs by enhancing the activities of protein phosphatases. To test this, HEL cells were treated for 6 hours with pervanadate to achieve a broad range inhibition of protein phosphatases. In such cells, the level of tyrosine phosphorylated STATs was moderately increased. Concomitant treatment with arsenic trioxide, still resulted in reduced phosphorylation of STATs (data not shown), suggesting that arsenic trioxide did not exert its inhibitory effect through vanadate-sensitive phosphatase activity.

Arsenic trioxide modulates PTKs, including ZNF198/FGFR1, leading to decreased phosphorylation of STATs. The attenuating effect of arsenic trioxide on STATs (Figs. 1 and 3) has been interpreted to mean that arsenic trioxide alters the activities of one or more PTKs that are able to phosphorylate STAT. The proposed causal relationship between arsenic trioxide–sensitive PTK action and STAT phosphorylation could not be defined in primary AML cells because we do not know the identity of the PTKs that are responsible for the constitutive activation of STATs. Therefore, we chose to test the kinase inhibitory effects of arsenic trioxide on several defined oncogenic PTKs in cell culture models. The first model consisted of cells expressing ZNF198/FGFR1, a novel PTK cloned by us (26). This is a 150-kDa protein resulting from fusion between the zinc-finger protein ZNF198 on chromosome 13q12 and FGFR1 on chromosome 8p11. The translocation has been found to be the sole genomic alteration that leads to a myeloproliferative disorder that can progress to either B- or T-lineage acute lymphoblastic leukemia. The resulting chimeric gene product exhibits constitutive kinase activity of the FGFR1 cytoplasmic domain, and this activity, when expressed in cells, confers a continuous stimulation of the STAT pathway (Fig. 5A ; ref. 11). Remarkably, arsenic trioxide treatment of cells expressing ZNF198/FGFR1 altered the phosphorylation of the kinase, as shown by increased molecular size and increased reaction with anti-phosphotyrosine, although the total amount of the fusion kinase, as detected by anti-FGFR1 immunoblotting, decreased. During arsenic trioxide treatment, the kinase changed its cytoplasmic localization from predominant concentration in aggregates to a more uniform distribution (Fig. 5B). Although the phosphorylation of the kinase was elevated, the kinase activity decreased, resulting in an arsenic trioxide dose-dependent reduction of STAT3 protein phosphorylation (Fig. 5A) but retaining constant total STAT3 protein level. Finally, the arsenic trioxide–dependent inhibition of protein tyrosine phosphorylation by FGFR1 kinase could also be shown with a second oncogenic fusion protein that combined BCR with FGFR1 (Fig. 5C). However, the arsenic trioxide–induced decrease of the electrophoretic mobility noted for the ZNF198/FGFR1 was not observed with the BCR/FGFR1 chimera or any other PTKs that were tested.

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Arsenic trioxide modulates oncogenic and non-oncogenic PTKs. 293 cells in six-well plates were transfected with the expression vectors for ZNF198/FGFR1 (A), GFP-tagged-ZNF198/FGFR1 (B), BCR/FGFR1 (C), BCR/ABL (C), JAK1 (D), or JAK2 (D; 4 μg DNA per well). The cells were treated 24 hours later with the indicated concentration of arsenic trioxide (A and B) 5 μmol/L (C and D) for 6 hours. Cells were extracted, and aliquots of each extract were electrophoresed on separate gels. The blots with transferred proteins were reacted with antibody (left). Positions of the transfected proteins (right). B, fluorescent images of the transfected cells were taken at ×40 magnification.

The modulatory action of arsenic trioxide on PTKs could also be confirmed for the oncogenic BCR/ABL (Fig. 5C), FLT3 (Fig. 1B), v-SRC, and FMS (data not shown) and even the normal forms of JAK1 and JAK2 (Fig. 5D). The modulating effect of arsenic trioxide on JAKs suggested that arsenic trioxide could attenuate the STAT-dependent signaling reactions of cytokine receptors that involve JAK1 or JAK2. This was shown by a decreased transcription of a STAT3-responsive gene in IL-6-treated cells (Fig. 6, left ). Moreover, the arsenic trioxide–dependent inhibition of the constitutively active oncogenic kinases similarly lowered the transcriptional stimulation of the STAT-responsive reporter gene (Fig. 6, right). The time-dependent reduction of STAT activity correlated with an apparent loss of protein in the case of PML and BCR/ABL (Fig. 7A ) but, interestingly, not for BCR/FGFR1 and the JAKs. In the latter two cases, the inhibition of the enzymatic activity of the kinases seems sufficient to explain the reduction in STAT signaling (Fig. 5C and D; data not shown).

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Arsenic trioxide decreased transcription of the STAT3. HepG2 cells were transfected with p(5xHPX-IL-6RE)-CAT (15 μg/mL) together with an empty expression vector, or an expression vector for ZNF198/FGFR1 or BCR/ABL (at the top of the panels). The subcultures of the transfected cells were treated for 24 hours with medium alone or with arsenic trioxide. Columns, mean PhosphorImager quantification of the fold stimulation values relative to the untreated vector control culture in three independently done experiments; bars, SD. *, P < 0.05; **, P < 0.005.

Fig. 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 7.

Arsenic trioxide mediates a modification of ZNF198/FGFR1 distinct from PML and BCR/ABL. A, arsenic trioxide mediated degradation of PML is kinetically distinct from change in phosphorylation of BCR/ABL, ZNF198/FGFR1 or STAT3. 293 cells transfected with PML, BCR/ABL, ZNF198/FGFR1, and STAT3 were exposed to 5 μmol/L arsenic trioxide and harvested at different time points. Total cell extracts were subjected to immunoblotting with the corresponding antibody. B, arsenic trioxide requires the cell environment to exert its effect on ZNF198/FGFR1. 293 cells were transfected with ZNF198/FGFR1, and subcultures were treated for 30 minutes with medium alone (control cells) or medium with 5 μmol/L arsenic trioxide (ATO cells). Cytosolic extracts were prepared from each culture. Aliquots from the control cells were incubated with arsenic trioxide at the indicated concentrations for 30 minutes at 37°C followed by Western blot analysis with the anti-FGFR1 antibody. An aliquot of extract from arsenic trioxide cells was incubated for 30 minutes without arsenic trioxide and served as indicator for potential, arsenic trioxide–independent modifications during the cell-free reaction.

PML is known to undergo degradation by sumolation following exposure to arsenic trioxide (27). We therefore compared the effect of arsenic trioxide on PML to its effect on phosphorylated ZNF198/FGFR1, STAT3, and BCR/ABL over time (Fig. 7A). In the first 15 to 30 minutes of incubation with arsenic trioxide, PML underwent close to complete degradation. In contrast, the loss of the BCR/ABL and the molecular weight changes of ZNF198/FGFR1 occurred with much slower kinetics. This suggests that arsenic trioxide's mechanism of action is target dependent.

Finally, to determine whether arsenic trioxide's effect is kinase selective, such as through a direct chemical reaction of arsenic trioxide with the kinase protein or whether it depends on the intracellular environment, we tested arsenic trioxide's effect on ZNF198/FGFR1 in cell-free conditions. As shown in Fig. 7B, arsenic trioxide, even at high concentrations, did not modify the electrophoretic mobility of ZNF198/FGFR1 protein when incubated in cell-free extracts, suggesting that arsenic trioxide exerts its effect through cellular mediators.

Taken together, these data support the conclusion that arsenic trioxide acts as a broad-spectrum PTK inhibitor. The mechanism of action does not seem to include phosphatase activation but involves altered PTK activities, changes in protein modification, inactivation, and decreased expression of the PTK protein.

Discussion

We have shown that arsenic trioxide inhibits PTKs and thereby indirectly decreases activation of STAT proteins. Arsenic trioxide caused a change in the molecular weight of ZNF198/FGFR1, altered its intracellular distribution, and induced progressive loss of the protein. Arsenic trioxide modulation of ZNF198/FGFR1 was reproduced for hematopoietic oncogenic (FLT3 and BCR/ABL) and non-oncogenic (JAK1 and JAK2) PTKs. To the best of our knowledge, such information has not been previously reported. Moreover, our model provides measurable readouts for arsenic trioxide effects.

Arsenic trioxide has been found to induce growth inhibition through mitotic arrest before apoptosis in cancer cells (28, 29). The cells are arrested in the early phases of mitosis prophase, premetaphase, and metaphase (28); this effect is distinct from anti-tubulin agents, such as paclitaxel (29). It is not clear why in HEL cells we detected more necrosis than apoptosis.

Arsenic trioxide inhibition of STAT3, preceding inhibition of cellular proliferation, has been described by Hayashi et al. (8) in multiple myeloma cells. In that system, STAT3 activity was induced by IL-6. Although Schuringa et al. (30) suggested that constitutive STAT3 activity in AML blasts resulted from autocrine secretion of IL-6, IL-6 is known to be inhibitory for AML proliferation (31). Therefore, the role of IL-6-induced STAT3 activation in leukemogenesis remains unclear. Other growth factors, including thrombopoietin and granulocyte colony-stimulating factor, are also known to activate STAT3 (32, 33). In that regard, in view of our demonstration of modulation of JAK1 and JAK2 activity by arsenic trioxide, it is likely that arsenic trioxide will affect resident PTKs upstream of the STATs, if induced by a ligand in AML.

Cellular transformation triggered by various tyrosine kinase oncoproteins, such as v-SRC and LCK, has also been associated with constitutive activation of STAT3 (34, 35), but involvement of these oncoproteins has not been shown in AML and cannot explain the high proportion of cases with constitutive STAT3 activity in this disease. Other, yet unidentified, oncogenic PTKs may be involved in inducing constitutive STAT3 activity in AML. In that regard, ZNF198/FGFR1 offered a model for understanding the mechanism of action of arsenic trioxide on oncogenic PTKs.

STAT5 activation by oncogenic tyrosine kinases has been described in BCR/ABL–expressing (36, 37) and FLT3-ITD–expressing (38, 39) cells. Targeted down-regulation of these two oncogenic proteins resulted in down-regulation of STAT5 [BCR/ABL (40) and FLT3-ITD (20, 41)]. Therefore, the effect of arsenic trioxide on these two oncogenic tyrosine kinases and their downstream pathways (e.g., STAT5) lend credence to our hypothesis that arsenic trioxide's effect on STAT proteins is attributed to its effect on PTKs.

Several mechanisms are proposed to explain the increased molecular weight of ZNF198/FGFR1 following exposure to arsenic trioxide. Reactive oxygen species generated in response to arsenic trioxide lead to accumulation of hydrogen peroxide (42). These will, in turn, affect sulfhydryl groups, which are known to be involved in refolding of proteins (43). However, treatment of cells with redox reactions, including H2O2, UV radiation, and photodynamic therapy, were unable to reproduce the modification. This suggests an arsenic trioxide-specific event. Sumolation, or covalent binding of SUMO-1, a ubiquitin-like polypeptide, to its target is one possible mechanism to explain the increased molecular weight of ZNF198/FGFR1 following exposure to arsenic trioxide. This is supported by our previous findings that ZNF198/FGFR1 binds to another ubiquitin-like protein HHR6 (44). Arsenic trioxide has been shown to induce binding of SUMO-1 to PML (27) and IκB (45), leading to changes in conformation. Of interest is that both PML and ZNF198 contain zinc finger-like domains, and that they both undergo changes in response to arsenic trioxide within 15 to 30 minutes.

Redistribution of proteins in response to arsenic trioxide has been well recognized previously. Arsenite (NaAsO2) has been shown to induce aggregation of THY-1, a glycoprotein located on the membrane of early progenitor cells (46). This effect required interactions with sulfhydryl groups (46). Furthermore, in acute promyelocytic leukemia cells, arsenic trioxide was shown to target PML proteins into nuclear bodies, leading to their degradation (47). This effect is believed to result from sumolation of PML (47). Our demonstration of redistribution of ZNF198/FGFR1 from concentrated cytoplasmic aggregates to a more uniform pattern upon exposure to arsenic trioxide is therefore in line with the published literature. Additional work will determine whether this effect of arsenic trioxide is dependent on sulfhydryl groups or on other mechanisms.

Arsenic trioxide was shown to induce degradation of other proteins, in addition to PML/retinoic acid receptor α (8, 42) (e.g., AKT; named after the acute transforming retrovirus) protein in the absence of an effect on phosphorylation (8). More difficult to explain is why some proteins are degraded (ZNF198/FGFR1 and BCR/ABL), whereas others (BCR/FGFR1, FLT3, JAK1, JAK2, and STATs) are not. One possible explanation may be the half-life of the proteins. For example, the half-life of BCR/ABL was estimated to be ∼48 hours (48), and at least 48 hours were required to notice a change in its phosphorylation. Others have shown similar results and the mechanism to be arsenic trioxide–dependent reduction of mRNA translation (49). Therefore, at this point, it is unclear whether arsenic trioxide primarily reduces synthesis of the kinases or enhances their degradation.

In summary, our work supports previous findings that arsenic trioxide induces death of non–acute promyelocytic leukemia AML cells (5, 6) and partially elucidates its mechanism of action. However, arsenic trioxide given as a single agent did not significantly improve the outcome of patients with relapsed or refractory AML (50). We therefore propose phase I clinical trials of arsenic trioxide to study the in vivo arsenic trioxide effects on the signaling pathways.

Footnotes

  • Grant support: National Cancer Institute grants CA16056 (M. Wetzler, J.K. Cowell, and H. Baumann), CA76167 (J.K. Cowell), CA85580 (H. Baumann), and CA99238 (M. Wetzler); Cell Therapeutic, Inc., Seattle, WA (M. Wetzler); and The Heidi Leukemia Research Fund, Buffalo, NY (M. Wetzler).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Note: Current address for K.A. Donohue: Duke Cancer Statistical Center, Durham, North Carolina. Current address for A. Mortazavi: The Ohio State University-James Cancer Hospital, Columbus, Ohio. Current address for A.A. McDonald: VA Western New York Healthcare System, Buffalo, New York.

    • Accepted August 28, 2006.
    • Received June 5, 2006.
    • Revision received August 4, 2006.

References

  1. ↵
    Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940–54.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 1998;58:3173–80.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002;99:252–7.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354–60.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 2001;112:783–6.
    OpenUrlCrossRefPubMed
  6. ↵
    Lehmann S, Bengtzen S, Paul A, Christensson B, Paul C. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 2001;66:357–64.
    OpenUrlCrossRefPubMed
  7. ↵
    Hong SH, Yang Z, Privalsky ML. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor α oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 2001;21:7172–82.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002;1:851–60.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Steensma DP, McClure RF, Karp JE, et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006;20:971–8.
    OpenUrlCrossRefPubMed
  10. ↵
    Ng J, Cantrell D. STAT3 is a serine kinase target in T lymphocytes. Interleukin 2 and T cell antigen receptor signals converge upon serine 727. J Biol Chem 1997;272:24542–9.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Baumann H, Kunapuli P, Tracy E, Cowell JK. The oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors. J Biol Chem 2003;278:16198–208.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D. FLT3/ITD mutation signaling includes suppression of SHP-1. J Biol Chem 2005;280:5361–9.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001;98:3778–83.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–30.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996;87:882–6.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991;11:2057–65.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Zhuang H, Patel SV, He TC, Sonsteby SK, Niu Z, Wojchowski DM. Inhibition of erythropoietin-induced mitogenesis by a kinase-deficient form of Jak2. J Biol Chem 1994;269:21411–4.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Wang Y, Ripperger J, Fey GH, et al. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells. Hepatology 1999;30:682–97.
    OpenUrlCrossRefPubMed
  19. ↵
    Morella KK, Lai CF, Kumaki S, et al. The action of interleukin-2 receptor subunits defines a new type of signaling mechanism for hematopoietin receptors in hepatic cells and fibroblasts. J Biol Chem 1995;270:8298–310.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99:3885–91.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Sadowski HB, Shuai K, Darnell JE, Jr., Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993;261:1739–44.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Brechner T, Hocke G, Goel A, Fey GH. Interleukin 6 response factor binds co-operatively at two adjacent sites in the promoter upstream region of the rat α 2-macroglobulin gene. Mol Biol Med 1991;8:267–85.
    OpenUrlPubMed
  23. ↵
    Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 1910;40:iv–vii.
    OpenUrl
  24. ↵
    Levasseur LM, Faessel H, Slocum HK, Greco WR. Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay. J Pharmacokinet Biopharm 1998;26:717–33.
    OpenUrlCrossRefPubMed
  25. ↵
    Neter J, Wasserman W, Kunter MH. Applied linear statistical models. Boston (MA): McGraw-Hill College; 1990. p. 160–2.
  26. ↵
    Still IH, Cowell JK. The t(8;13) atypical myeloproliferative disorder: further analysis of the ZNF198 gene and lack of evidence for multiple genes disrupted on chromosome 13. Blood 1998;92:1456–8.
    OpenUrlFREE Full Text
  27. ↵
    Lallemand-Breitenbach V, Zhu J, Puvion F, et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor α degradation. J Exp Med 2001;193:1361–71.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Halicka HD, Smolewski P, Darzynkiewicz Z, Dai W, Traganos F. Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle 2002;1:201–9.
    OpenUrlPubMed
  29. ↵
    Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62:529–38.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000;95:3765–70.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Koistinen P, Saily M, Poromaa N, Savolainen ER. Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia. Acta Haematol 1997;98:14–21.
    OpenUrlPubMed
  32. ↵
    Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996;87:439–46.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Chakraborty A, Tweardy DJ. Stat3 and G-CSF-induced myeloid differentiation. Leuk Lymphoma 1998;30:433–42.
    OpenUrlPubMed
  34. ↵
    Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998;18:2553–8.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998;18:2545–52.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811–20.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997;159:4720–8.
    OpenUrlAbstract
  38. ↵
    Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624–31.
    OpenUrlCrossRefPubMed
  39. ↵
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003;9:2140–50.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Mow BM, Chandra J, Svingen PA, et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002;99:664–71.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Lopes de Menezes DE, Peng J, Garrett EN, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281–91.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893–903.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Qiao ZS, Min CY, Hua QX, Weiss MA, Feng YM. In vitro refolding of human proinsulin. Kinetic intermediates, putative disulfide-forming pathway folding initiation site, and potential role of C-peptide in folding process. J Biol Chem 2003;278:17800–9.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Kunapuli P, Somerville R, Still IH, Cowell JK. ZNF198 protein, involved in rearrangement in myeloproliferative disease, forms complexes with the DNA repair-associated HHR6A/6B and RAD18 proteins. Oncogene 2003;22:3417–23.
    OpenUrlCrossRefPubMed
  45. ↵
    Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol Cell 1998;2:233–9.
    OpenUrlCrossRefPubMed
  46. ↵
    Hossain K, Akhand AA, Kato M, et al. Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase. J Immunol 2000;165:4290–7.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998;17:61–70.
    OpenUrlAbstract
  48. ↵
    Dhut S, Chaplin T, Young BD. BCR-ABL and BCR proteins: biochemical characterization and localization. Leukemia 1990;4:745–50.
    OpenUrlPubMed
  49. ↵
    Nimmanapalli R, Bali P, O'Bryan E, et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003;63:7950–8.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 2004;28:909–19.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 12 (22)
November 2006
Volume 12, Issue 22
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation
Meir Wetzler, Michael T. Brady, Erin Tracy, Zhang-Rong Li, Kathleen A. Donohue, Kieran L. O'Loughlin, Yijun Cheng, Amir Mortazavi, Amy A. McDonald, Padmaja Kunapuli, Paul K. Wallace, Maria R. Baer, John K. Cowell and Heinz Baumann
Clin Cancer Res November 15 2006 (12) (22) 6817-6825; DOI: 10.1158/1078-0432.CCR-06-1354

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation
Meir Wetzler, Michael T. Brady, Erin Tracy, Zhang-Rong Li, Kathleen A. Donohue, Kieran L. O'Loughlin, Yijun Cheng, Amir Mortazavi, Amy A. McDonald, Padmaja Kunapuli, Paul K. Wallace, Maria R. Baer, John K. Cowell and Heinz Baumann
Clin Cancer Res November 15 2006 (12) (22) 6817-6825; DOI: 10.1158/1078-0432.CCR-06-1354
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Targeting HER2 with Osimertinib in NSCLC
  • Combined VEGF/EGFR Inhibition
  • Radiotherapy with IDO1/PD-1 Blockade Treats Advanced GBM
Show more Cancer Therapy: Preclinical
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement